Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura
  • Serra Camprubí, Queralt
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni|||0000-0002-6852-4834
  • Cannatá, Chiara|||0000-0003-4807-4669
  • Espinar, Lorena|||0000-0003-3881-3886
  • Querol, Jessica|||0000-0002-0527-759X
  • García-López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis|||0000-0002-6441-0688
  • Miró Canturri, Andrea
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Serra, Violeta|||0000-0001-6620-1065
  • Serrano, Luis|||0000-0002-5276-1392
  • Tian, Tian|||0000-0002-9906-0980
  • Peiró, Sandra|||0000-0001-9519-3877
  • Sdelci, Sara|||0000-0003-1330-4364
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC. Investigation of the molecular mechanisms underlying triple-negative breast cancer (TNBC) proliferation led to the identification of new therapeutic vulnerabilities.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Detection of differential bait proteoforms through immunoprecipitation-mass spectrometry data analysis

  • Kourtis, Savvas
  • Cianferoni, Damiano
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Proteins are often referred to as the workhorses of cells, and their interactions are necessary to facilitate specific cellular functions. Despite the recognition that protein-protein interactions, and thus protein functions, are determined by proteoform states, such as mutations and post-translational modifications (PTMs), methods for determining the differential abundance of proteoforms across conditions are very limited. Classically, immunoprecipitation coupled with mass spectrometry (IP-MS) has been used to understand how the interactome (preys) of a given protein (bait) changes between conditions to elicit specific cellular functions. Reversing this concept, we present here a new workflow for IP-MS data analysis that focuses on identifying the differential peptidoforms of the bait protein between conditions. This method can provide detailed information about specific bait proteoforms, potentially revealing pathogenic protein states that can be exploited for the development of targeted therapies., The Sdelci lab’s contributions to this study were funded by an ERC Starting Grant (ERC-StG-852343-EPICAMENTE).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Native chromatome profiling reveals hundreds of metabolic enzymes in the nucleus across tissues

  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Elbæk, Camilla Reiter
  • Schmidt, Alisa
  • Ghose, Ritobrata
  • Coll-Manzano, Albert
  • Espinar, Lorena
  • Guirola, Maria
  • Pardo-Lorente, Natalia
  • Garcia-Cao, Marta
  • Pfeiffer, Matilda
  • Haynes, Samuel
  • Fontaine, Frédéric
  • Müller, André
  • Sdelci, Sara
Metabolic and epigenetic rewiring are hallmarks of cancer, with increasing evidence suggesting crosstalk between these processes. While previous studies have hinted at the role of metabolic enzymes in the nucleus, the extent and functional relevance of their nuclear localization remain unclear. In this study, we present a comprehensive chromatome proteomic analysis across cancer lineages and healthy samples, revealing that metabolic enzyme moonlighting on chromatin is widespread across various tissues and metabolic pathways. We show that the abundance of metabolic enzymes on chromatin is tissue-specific, with oxidative phosphorylation proteins notably depleted in lung cancer, suggesting a link between nuclear metabolism and cell identity. Further, we explore the dynamic chromatin association of one-carbon folate enzymes, demonstrating their involvement in DNA damage and repair processes. Finally, we asked whether restricting metabolic enzymes to specific subcellular compartments rewires the transcriptome, thereby decoupling the observed transcriptional changes from mere metabolite diffusion. Our findings propose and validate novel non-canonical nuclear roles for several metabolic enzymes, providing new insights into the functional relationship between metabolism and chromatin regulation. This study underscores the hypothesis that the nucleus is populated by metabolic enzymes, offering new avenues for understanding how nuclear metabolism impacts chromatin function and cancer progression., We acknowledge support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program and to the EMBL partnership. A.S. acknowledges financial support of a fellowship from the Marie Sklodowska-Curie Doctoral Network NUCLEAR (grant agreement no. 101166838). M.P. acknowledges financial support of a fellowship from the “la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/DI23/11990062. S.S. acknowledges financial support from the Spanish Ministry of Science and Innovation through the Plan Nacional (grant agreement no. PID2022-141740NB-I00), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 852343). R.G. acknowledges financial support of a Severo Ochoa predoctoral fellowship. N.P.L. acknowledges financial support of a fellowship from the Boehringer Foundation. We thank Queralt Tolosa Ramon for creating the illustrations for OXPHOS complexes in Fig. 2, which are subject to a CC BY-NC-SA (Attribution-NonCommercial-ShareAlike) 4.0 International license.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Nuclear localization of MTHFD2 is required for correct mitosis progression

  • Pardo-Lorente, Natalia
  • Gkanogiannis, Anestis
  • Cozzuto, Luca
  • Gañez-Zapater, Antoni
  • Espinar, Lorena
  • Ghose, Ritobrata
  • Severino, Jacqueline, 1990-
  • García-López, Laura
  • Aydin, Rabia Gül
  • Martin, Laura
  • Neguembor, Maria Victoria
  • Darai, Evangelia
  • Cosma, Maria Pia
  • Batlle-Morera, Laura
  • Ponomarenko, Julia
  • Sdelci, Sara
Subcellular compartmentalization of metabolic enzymes establishes a unique metabolic environment that elicits specific cellular functions. Indeed, the nuclear translocation of certain metabolic enzymes is required for epigenetic regulation and gene expression control. Here, we show that the nuclear localization of the mitochondrial enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) ensures mitosis progression. Nuclear MTHFD2 interacts with proteins involved in mitosis regulation and centromere stability, including the methyltransferases KMT5A and DNMT3B. Loss of MTHFD2 induces severe methylation defects and impedes correct mitosis completion. MTHFD2 deficient cells display chromosome congression and segregation defects and accumulate chromosomal aberrations. Blocking the catalytic nuclear function of MTHFD2 recapitulates the phenotype observed in MTHFD2 deficient cells, whereas restricting MTHFD2 to the nucleus is sufficient to ensure correct mitotic progression. Our discovery uncovers a nuclear role for MTHFD2, supporting the notion that translocation of metabolic enzymes to the nucleus is required to meet precise chromatin needs., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. We would like to thank the CRG and CNAG Sequencing Facilities (Barcelona, Spain) for all next-generation sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the MTHFD2 interactome analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the sorting, the IMIM Platform for molecular cytogenetics (Barcelona, Spain) for the karyotype analysis, and MARbiobank for provision of patient samples for organoid generation. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We would like to thank Prof. Thomas Helleday for providing the MTHFD2 inhibitor TH9619 and for the fruitful discussions. N.P.L. was supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 852343, ERC-StG-852343-EPICAMENTE) and from a Spanish Plan Estatal grant (Ministerio de Ciencia e Innovación, Project PID2019-110598GA-I00 funded by MICIU/AEI /10.13039/501100011033).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Hallmarks of nuclear metabolism: implications for genome integrity, nuclear signaling, and therapeutic targeting

  • Schmidt, Alisa
  • Pfeiffer, Matilda
  • Sdelci, Sara
Certain metabolic enzymes localize to the nucleus, where they perform regulatory functions that extend far beyond canonical metabolism. Once inside, they influence chromatin organization, transcription, DNA repair, and cell cycle progression. This review summarizes recent advances that redefine metabolism as a nuclear process and reshape our understanding of metabolic regulation. It further defines the emerging hallmarks of nuclear metabolism and discusses how these insights open new avenues for cancer therapies., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program, and to the EMBL partnership. A.S. acknowledges financial support of a fellowship from the Marie Sklodowska-Curie Doctoral Network NUCLEAR (grant agreement no. 101166838). M.P. acknowledges financial support of a fellowship from the 'la Caixa' Foundation (ID 100010434). The fellowship code is LCF/BQ/DI23/11990062. S.S. acknowledges financial support from the Spanish Ministry of Science and Innovation through the Plan Nacional (grant agreement no. PID2022-141740NB-I00), the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 852343).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability

  • Moretton, Amandine
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Calabrò, Chiara
  • Espinar, Lorena
  • Fontaine, Frédéric
  • Darai, Evangelia
  • Abad Cortel, Etna
  • Block, Samuel
  • Pascual-Reguant, Laura, 1990-
  • Pardo-Lorente, Natalia
  • Ghose, Ritobrata
  • Vander Heiden, Matthew G.
  • Janic, Ana
  • Müller, André C.
  • Loizou, Joanna I.
  • Sdelci, Sara
While cellular metabolism impacts the DNA damage response, a systematic understanding of the metabolic requirements that are crucial for DNA damage repair has yet to be achieved. Here, we investigate the metabolic enzymes and processes that are essential for the resolution of DNA damage. By integrating functional genomics with chromatin proteomics and metabolomics, we provide a detailed description of the interplay between cellular metabolism and the DNA damage response. Further analysis identified that Peroxiredoxin 1, PRDX1, contributes to the DNA damage repair. During the DNA damage response, PRDX1 translocates to the nucleus where it reduces DNA damage-induced nuclear reactive oxygen species. Moreover, PRDX1 loss lowers aspartate availability, which is required for the DNA damage-induced upregulation of de novo nucleotide synthesis. In the absence of PRDX1, cells accumulate replication stress and DNA damage, leading to proliferation defects that are exacerbated in the presence of etoposide, thus revealing a role for PRDX1 as a DNA damage surveillance factor., AM and CC were funded by the Austrian Science Fund (grant number P 33024 awarded to JIL). The Loizou lab is funded by an ERC Synergy Grant (DDREAMM Grant agreement ID: 855741). The Sdelci lab's contributions to this study were funded by an ERC Starting Grant (ERC-StG-852343-EPICAMENTE). This work was funded, in part, by a donation from Benjamin Landesmann. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. CeMM is funded by the Austrian Academy of Sciences. MGVH acknowledges funding from R35CA242379, the Lustgarten Foundation, the Ludwig Center at MIT, and the MIT Center for Precision Cancer Medicine.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity

  • Espinar, Lorena
  • Garcia-Cao, Marta
  • Schmidt, Alisa
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Aranda Vallejo, Carla
  • Ghose, Ritobrata
  • García-López, Laura
  • Sheraj, Ilir
  • Pardo-Lorente, Natalia
  • Bantulà, Marina
  • Pascual-Reguant, Laura, 1990-
  • Darai, Evangelia
  • Guirola, Maria
  • Montero, Joan
  • Sdelci, Sara
Nuclear metabolism and DNA damage response are intertwined processes, but the precise molecular links remain elusive. Here, we explore this crosstalk using triple-negative breast cancer (TNBC) as a model, a subtype often prone to DNA damage accumulation. We show that the de novo purine synthesis enzyme IMPDH2 is enriched on chromatin in TNBC compared to other subtypes. IMPDH2 chromatin localization is DNA damage dependent, and IMPDH2 repression leads to DNA damage accumulation. On chromatin, IMPDH2 interacts with and modulates PARP1 activity by controlling the nuclear availability of NAD+ to fine-tune the DNA damage response. However, when IMPDH2 is restricted to the nucleus, it depletes nuclear NAD+, leading to PARP1 cleavage and cell death. Our study identifies a non-canonical nuclear role for IMPDH2, acting as a convergence point of nuclear metabolism and DNA damage response., The authors would like to thank the Genomics Unit at the CRG for assistance with the sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the chromatome MS analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the cell cycle analysis, Dr. Ivan Perez-Nuñez from Dr. Toni Celià-Terrassa group (IMIM, Barcelona, Spain) for helping with the IHC analysis. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. N.P.L. is supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. L.P.R. is supported by a Fundación Francisco Cobo (Eduardo Gallego) postdoctoral fellowship. The Sdelci lab’s contributions to this study have received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 852343), and from the Spanish Plan Estatal grants (Ministerio de Ciencia e Innovación, PID2019-110598GA-I00/AEI/10.13039/501100011033 and PID2022-141740NB-I00 funded by MICIU /AEI /10.13039/501100011033 / FEDER, UE) and from Fundación BBVA under Beca Leonardo a Investigadores y Creadores Culturales 2022 (LEO22-2-2290-BBM-BAS-167).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nuclear localization of MTHFD2 is required for correct mitosis progression

  • Pardo-Lorente, Natalia
  • Gkanogiannis, Anestis
  • Cozzuto, Luca
  • Gañez Zapater, Antoni
  • Espinar, Lorena
  • Ghose, Ritobrata
  • Severino, Jacqueline
  • García-López, Laura
  • Gül Aydin, Rabia
  • Martin, Laura
  • Neguembor, Maria Victoria
  • Darai, Evangelia
  • Cosma, Maria Pia
  • Batlle-Morera, Laura
  • Ponomarenko, Julia
  • Sdelci, Sara
Subcellular compartmentalization of metabolic enzymes establishes a unique metabolic environment that elicits specific cellular functions. Indeed, the nuclear translocation of certain metabolic enzymes is required for epigenetic regulation and gene expression control. Here, we show that the nuclear localization of the mitochondrial enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) ensures mitosis progression. Nuclear MTHFD2 interacts with proteins involved in mitosis regulation and centromere stability, including the methyltransferases KMT5A and DNMT3B. Loss of MTHFD2 induces severe methylation defects and impedes correct mitosis completion. MTHFD2 deficient cells display chromosome congression and segregation defects and accumulate chromosomal aberrations. Blocking the catalytic nuclear function of MTHFD2 recapitulates the phenotype observed in MTHFD2 deficient cells, whereas restricting MTHFD2 to the nucleus is sufficient to ensure correct mitotic progression. Our discovery uncovers a nuclear role for MTHFD2, supporting the notion that translocation of metabolic enzymes to the nucleus is required to meet precise chromatin needs., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. We would like to thank the CRG and CNAG Sequencing Facilities (Barcelona, Spain) for all next-generation sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the MTHFD2 interactome analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the sorting, the IMIM Platform for molecular cytogenetics (Barcelona, Spain) for the karyotype analysis, and MARbiobank for provision of patient samples for organoid generation. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We would like to thank Prof. Thomas Helleday for providing the MTHFD2 inhibitor TH9619 and for the fruitful discussions. N.P.L. was supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 852343, ERC-StG-852343-EPICAMENTE) and from a Spanish Plan Estatal grant (Ministerio de Ciencia e Innovación, Project PID2019-110598GA-I00 funded by MICIU/AEI /10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001049-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hallmarks of nuclear metabolism: implications for genome integrity, nuclear signaling, and therapeutic targeting

  • Schmidt, Alisa
  • Pfeiffer, Matilda
  • Sdelci, Sara
Certain metabolic enzymes localize to the nucleus, where they perform regulatory functions that extend far beyond canonical metabolism. Once inside, they influence chromatin organization, transcription, DNA repair, and cell cycle progression. This review summarizes recent advances that redefine metabolism as a nuclear process and reshape our understanding of metabolic regulation. It further defines the emerging hallmarks of nuclear metabolism and discusses how these insights open new avenues for cancer therapies., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program, and to the EMBL partnership. A.S. acknowledges financial support of a fellowship from the Marie Sklodowska-Curie Doctoral Network NUCLEAR (grant agreement no. 101166838). M.P. acknowledges financial support of a fellowship from the 'la Caixa' Foundation (ID 100010434). The fellowship code is LCF/BQ/DI23/11990062. S.S. acknowledges financial support from the Spanish Ministry of Science and Innovation through the Plan Nacional (grant agreement no. PID2022-141740NB-I00), the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 852343).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity

  • Espinar, Lorena
  • Garcia-Cao, Marta
  • Schmidt, Alisa
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Aranda Vallejo, Carla
  • Ghose, Ritobrata
  • García-López, Laura
  • Sheraj, Ilir
  • Pardo Lorente, Natalia
  • Bantulà, Marina
  • Pascual-Reguant, Laura, 1990-
  • Darai, Evangelia
  • Guirola, Maria
  • Montero, Joan
  • Sdelci, Sara
Nuclear metabolism and DNA damage response are intertwined processes, but the precise molecular links remain elusive. Here, we explore this crosstalk using triple-negative breast cancer (TNBC) as a model, a subtype often prone to DNA damage accumulation. We show that the de novo purine synthesis enzyme IMPDH2 is enriched on chromatin in TNBC compared to other subtypes. IMPDH2 chromatin localization is DNA damage dependent, and IMPDH2 repression leads to DNA damage accumulation. On chromatin, IMPDH2 interacts with and modulates PARP1 activity by controlling the nuclear availability of NAD+ to fine-tune the DNA damage response. However, when IMPDH2 is restricted to the nucleus, it depletes nuclear NAD+, leading to PARP1 cleavage and cell death. Our study identifies a non-canonical nuclear role for IMPDH2, acting as a convergence point of nuclear metabolism and DNA damage response., The authors would like to thank the Genomics Unit at the CRG for assistance with the sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the chromatome MS analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the cell cycle analysis, Dr. Ivan Perez-Nuñez from Dr. Toni Celià-Terrassa group (IMIM, Barcelona, Spain) for helping with the IHC analysis. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. N.P.L. is supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. L.P.R. is supported by a Fundación Francisco Cobo (Eduardo Gallego) postdoctoral fellowship. The Sdelci lab’s contributions to this study have received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 852343), and from the Spanish Plan Estatal grants (Ministerio de Ciencia e Innovación, PID2019-110598GA-I00/AEI/10.13039/501100011033 and PID2022-141740NB-I00 funded by MICIU /AEI /10.13039/501100011033 / FEDER, UE) and from Fundación BBVA under Beca Leonardo a Investigadores y Creadores Culturales 2022 (LEO22-2-2290-BBM-BAS-167).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Nuclear localization of MTHFD2 is required for correct mitosis progression

  • Pardo Lorente, Natalia
  • Gkanogiannis, Anestis
  • Cozzuto, Luca
  • Gañez-Zapater, Antoni
  • Espinar, Lorena
  • Ghose, Ritobrata
  • Severino, Jacqueline, 1990-
  • García-López, Laura
  • Aydin, Rabia Gül
  • Martin, Laura
  • Neguembor, Maria Victoria
  • Darai, Evangelia
  • Cosma, Maria Pia
  • Batlle-Morera, Laura
  • Ponomarenko, Julia
  • Sdelci, Sara
Subcellular compartmentalization of metabolic enzymes establishes a unique metabolic environment that elicits specific cellular functions. Indeed, the nuclear translocation of certain metabolic enzymes is required for epigenetic regulation and gene expression control. Here, we show that the nuclear localization of the mitochondrial enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) ensures mitosis progression. Nuclear MTHFD2 interacts with proteins involved in mitosis regulation and centromere stability, including the methyltransferases KMT5A and DNMT3B. Loss of MTHFD2 induces severe methylation defects and impedes correct mitosis completion. MTHFD2 deficient cells display chromosome congression and segregation defects and accumulate chromosomal aberrations. Blocking the catalytic nuclear function of MTHFD2 recapitulates the phenotype observed in MTHFD2 deficient cells, whereas restricting MTHFD2 to the nucleus is sufficient to ensure correct mitotic progression. Our discovery uncovers a nuclear role for MTHFD2, supporting the notion that translocation of metabolic enzymes to the nucleus is required to meet precise chromatin needs., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. We would like to thank the CRG and CNAG Sequencing Facilities (Barcelona, Spain) for all next-generation sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the MTHFD2 interactome analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the sorting, the IMIM Platform for molecular cytogenetics (Barcelona, Spain) for the karyotype analysis, and MARbiobank for provision of patient samples for organoid generation. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We would like to thank Prof. Thomas Helleday for providing the MTHFD2 inhibitor TH9619 and for the fruitful discussions. N.P.L. was supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 852343, ERC-StG-852343-EPICAMENTE) and from a Spanish Plan Estatal grant (Ministerio de Ciencia e Innovación, Project PID2019-110598GA-I00 funded by MICIU/AEI /10.13039/501100011033).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Detection of differential bait proteoforms through immunoprecipitation-mass spectrometry data analysis

  • Kourtis, Savvas
  • Cianferoni, Damiano
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Proteins are often referred to as the workhorses of cells, and their interactions are necessary to facilitate specific cellular functions. Despite the recognition that protein-protein interactions, and thus protein functions, are determined by proteoform states, such as mutations and post-translational modifications (PTMs), methods for determining the differential abundance of proteoforms across conditions are very limited. Classically, immunoprecipitation coupled with mass spectrometry (IP-MS) has been used to understand how the interactome (preys) of a given protein (bait) changes between conditions to elicit specific cellular functions. Reversing this concept, we present here a new workflow for IP-MS data analysis that focuses on identifying the differential peptidoforms of the bait protein between conditions. This method can provide detailed information about specific bait proteoforms, potentially revealing pathogenic protein states that can be exploited for the development of targeted therapies., The Sdelci lab’s contributions to this study were funded by an ERC Starting Grant (ERC-StG-852343-EPICAMENTE).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability

  • Moretton, Amandine
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Calabrò, Chiara
  • Espinar Calvo, Maria Lorena
  • Fontaine, Frédéric
  • Darai, Evangelia
  • Abad Cortel, Etna
  • Block, Samuel
  • Pascual-Reguant, Laura, 1990-
  • Pardo-Lorente, Natalia
  • Ghose, Ritobrata
  • Vander Heiden, Matthew G.
  • Janic, Ana
  • Müller, André C.
  • Loizou, Joanna I.
  • Sdelci, Sara
While cellular metabolism impacts the DNA damage response, a systematic understanding of the metabolic requirements that are crucial for DNA damage repair has yet to be achieved. Here, we investigate the metabolic enzymes and processes that are essential for the resolution of DNA damage. By integrating functional genomics with chromatin proteomics and metabolomics, we provide a detailed description of the interplay between cellular metabolism and the DNA damage response. Further analysis identified that Peroxiredoxin 1, PRDX1, contributes to the DNA damage repair. During the DNA damage response, PRDX1 translocates to the nucleus where it reduces DNA damage-induced nuclear reactive oxygen species. Moreover, PRDX1 loss lowers aspartate availability, which is required for the DNA damage-induced upregulation of de novo nucleotide synthesis. In the absence of PRDX1, cells accumulate replication stress and DNA damage, leading to proliferation defects that are exacerbated in the presence of etoposide, thus revealing a role for PRDX1 as a DNA damage surveillance factor., AM and CC were funded by the Austrian Science Fund (grant number P 33024 awarded to JIL). The Loizou lab is funded by an ERC Synergy Grant (DDREAMM Grant agreement ID: 855741). The Sdelci lab's contributions to this study were funded by an ERC Starting Grant (ERC-StG-852343-EPICAMENTE). This work was funded, in part, by a donation from Benjamin Landesmann. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. CeMM is funded by the Austrian Academy of Sciences. MGVH acknowledges funding from R35CA242379, the Lustgarten Foundation, the Ludwig Center at MIT, and the MIT Center for Precision Cancer Medicine.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).